TABLE 2

Clinical Response of Lymphoma Patients to R-RIT

			¹³¹I-L19-SIP
Patient no.	Disease	Stage of disease	Activity (GBq)	Administrations of radioimmunotherapy	Best response and duration of response according to Cheson et al. (9)	Impact on clinical symptoms
2	SLL-NHL	IIIB	5.55	Only 1	Stable disease, 3 mo; died 3 mo later	No clinical benefit
3	HL	IIIBS	5.55	Only 1	PR, 1 mo	Symptom improvement for 8 mo, then clinical progression
4	HL	IVB	3.7	Only 1	PD	Progressing dyspnea from pulmonary (both lungs) and mediastinal lesions
5	HL	IVB	3.7	First	CR, 7 mo	Asthenia and fatigue relief; dyspnea disappearance
			3.7	Second	CR, 5 mo	Asthenia and fatigue relief
			3.7	Third	PR, 6 mo	Asthenia and fatigue relief; bone pain relief
			3.7	Fourth	PR, 6 mo	Asthenia and fatigue relief; bone pain relief
			3.7	Fifth	PD; died 6 mo later	Bone pain relief
12	HL	IVB	3.7	First	PR, 7 mo	Asthenia and fatigue relief
			3.7	Second	CR, 7 mo	Asymptomatic
13	HL	IVB	3.7	Only 1	PD; died 9 mo later	Back (bone) pain relief
14	HL	IVB	3.7	First	Stable disease, 6 mo, then PD	Neuropathic pain decrease, excellent symptomatic response, never stopped working, excellent quality of life
			3.7	Second	Stable disease, 7 mo	Neuropathic pain decrease
15	HL	IVB	3.7	First	Stable disease, 6 mo, then PD,	Fatigue relief
			3.7	Second	Stable disease, 3 mo, then PD, died	Fatigue relief
17	DLBCL	IIIA	3.70	Only 1	CR, 15 mo, ongoing	Asymptomatic
18	HL	IVB	1.85	Only 1	PD, patient still alive after ASCT	Asthenia, fatigue, and bone pain relief, improved quality of life